表紙:ダウン症(遺伝性疾患):開発中の薬剤(2021年)
市場調査レポート
商品コード
1000839

ダウン症(遺伝性疾患):開発中の薬剤(2021年)

Down Syndrome (Genetic Disorders) - Drugs in Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 100 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.49円
ダウン症(遺伝性疾患):開発中の薬剤(2021年)
出版日: 2021年03月31日
発行: Global Markets Direct
ページ情報: 英文 100 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ダウン症は、精神遅滞や発達遅延などの問題を引き起こす遺伝子疾患です。ダウン症は重症度が異なるため、発達障害も中等度から重度まで様々です。ダウン症の子供は、顔立ちがはっきりしています。すべてのダウン症の子供が同じ特徴を持っているわけではありませんが、より一般的な特徴としては、扁平な顔立ち、小さな頭、短い首、突出した舌、上向きの傾斜した目、特徴的な形の耳などが挙げられます。

当レポートは、ダウン症(遺伝性疾患)の開発中の薬剤について調査しており、世界の治療情勢、パイプライン治療法のレビュー、開発、パイプライン製品の薬剤プロファイル、主要企業のレビュー、ダウン症の治療に関する最新ニュースなどの包括的な情報を提供しています。

目次

  • イントロダクション
  • ダウン症-概要
  • ダウン症-治療法の開発
  • ダウン症-治療評価
  • ダウン症-治療法開発に関与する企業
  • ダウン症-薬剤プロファイル
  • ダウン症-休眠プロジェクト
  • ダウン症-製造中止製品
  • ダウン症-製品開発のマイルストーン
  • 付録
図表

List of Tables

  • Number of Products under Development for Down Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Down Syndrome - Pipeline by AC Immune SA, 2021
  • Down Syndrome - Pipeline by Aelis Farma SAS, 2021
  • Down Syndrome - Pipeline by Alzheon Inc, 2021
  • Down Syndrome - Pipeline by Annovis Bio Inc, 2021
  • Down Syndrome - Pipeline by Avanti Biosciences Inc, 2021
  • Down Syndrome - Pipeline by Balance Therapeutics Inc, 2021
  • Down Syndrome - Pipeline by Eisai Co Ltd, 2021
  • Down Syndrome - Pipeline by Elixirgen Therapeutics Inc, 2021
  • Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Down Syndrome - Pipeline by KinoPharma Inc, 2021
  • Down Syndrome - Pipeline by Laminar Pharmaceuticals SA, 2021
  • Down Syndrome - Pipeline by ManRos Therapeutics, 2021
  • Down Syndrome - Pipeline by NeuroCircuit Therapeutics Inc, 2021
  • Down Syndrome - Pipeline by NeuroNascent Inc, 2021
  • Down Syndrome - Pipeline by Prothena Corp Plc, 2021
  • Down Syndrome - Pipeline by San Biotechnology Co Ltd, 2021
  • Down Syndrome - Dormant Projects, 2021
  • Down Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Down Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12786IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Down Syndrome - Drugs in Development, 2021, provides an overview of the Down Syndrome (Genetic Disorders) pipeline landscape.

Down syndrome is a genetic disorder that causes lifelong mental retardation, developmental delays and other problems. Down syndrome varies in severity, so developmental problems range from moderate to serious. Children with Down syndrome have a distinct facial appearance. Though not all children with Down syndrome have the same features, some of the more common features are flattened facial features, small head, short neck, protruding tongue, upward slanting eyes, unusual for the child's ethnic group and unusually shaped ears. Children with Down syndrome may also have poor muscle tone, broad, short hands with a single crease in the palm, relatively short fingers and excessive flexibility.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Down Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Down Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Down Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Down Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Down Syndrome (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Down Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Down Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Down Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Down Syndrome (Genetic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Down Syndrome (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Down Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Down Syndrome - Overview
  • Down Syndrome - Therapeutics Development
  • Down Syndrome - Therapeutics Assessment
  • Down Syndrome - Companies Involved in Therapeutics Development
  • Down Syndrome - Drug Profiles
  • Down Syndrome - Dormant Projects
  • Down Syndrome - Discontinued Products
  • Down Syndrome - Product Development Milestones
  • Appendix